1
|
Cekała K, Trepczyk K, Sowik D, Karpowicz P, Giełdoń A, Witkowska J, Giżyńska M, Jankowska E, Wieczerzak E. Peptidomimetics Based on C-Terminus of Blm10 Stimulate Human 20S Proteasome Activity and Promote Degradation of Proteins. Biomolecules 2022; 12:biom12060777. [PMID: 35740902 PMCID: PMC9221443 DOI: 10.3390/biom12060777] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/24/2022] [Revised: 05/15/2022] [Accepted: 05/30/2022] [Indexed: 01/27/2023] Open
Abstract
Degradation of misfolded, redundant and oxidatively damaged proteins constitutes one of the cellular processes which are influenced by the 20S proteasome. However, its activity is generally thought to decrease with age which leads to the gradual accumulation of abnormal proteins in cells and their subsequent aggregation. Therefore, increasing proteasomal degradation constitutes a promising strategy to delay the onset of various age-related diseases, including neurodegenerative disorders. In this study we designed and obtained a series of peptidomimetic stimulators of 20S comprising in their sequences the C-terminal fragment of Blm10 activator. Some of the compounds were capable of enhancing the degradation of natively unfolded and oxidatively damaged proteins, such as α-synuclein and enolase, whose applicability as proteasome substrates was evaluated by microscale thermophoresis (MST). Furthermore, they increased the ChT-L activity of the proteasome in HEK293T cell extracts. Our studies indicate that the 20S proteasome-mediated protein substrates hydrolysis may be selectively increased by peptide-based stimulators acting in an allosteric manner. These compounds, after further optimization, may have the potential to counteract proteasome impairment in patients suffering from age-related diseases.
Collapse
|
2
|
Oud M, Breedveld S, Giżyńska M, Kroesen M, Hutschemaekers S, Habraken S, Petit S, Perkó Z, Heijmen B, Hoogeman M. MO-0794 Plan library based online adaptive IMPT for head and neck cancer. Radiother Oncol 2022. [DOI: 10.1016/s0167-8140(22)02430-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
3
|
Giżyńska M, Seppenwoolde Y, Heijmen B. OC-0359 A novel external/internal tracking algorithm mitigating respiratory motion baseline drifts. Radiother Oncol 2021. [DOI: 10.1016/s0167-8140(21)06874-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Giżyńska M, Rossi L, Den Toom W, Milder M, Inrocci L, De Vries K, Nuyttens J, Heijmen B. PO-1435: Large treatment plan quality enhancement in robotic radiotherapy. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)01453-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Giżyńska M, Blatkiewicz D, Bukat M, Gil-Ulkowska M, Maluszczak S, Paciorkiewicz A, Szałkowski D, Walewska A. PO-0911 Choose before you measure. Setting gamma parameters for different QA devices on the basis of ROC. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)31331-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
6
|
Giżyńska M, Bukat M, Szałkowski D, Walewska A. EP-1784 ArcCheck HU setting influence on the uncertainty of pre-treatment verification results. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32204-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
7
|
Walewska A, Giżyńska M, Fillmann M, Janiak P, Gruda M. EP-1792 Straightforward and easy way to determine MLC parameters (DLG, T) for FFF beams in Eclipse TPS. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32212-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
8
|
Walewska A, Giżyńska M, Paciorkiewicz A, Blatkiewicz D. EP-1794 Bias-free comparison of PTW arrays in terms of ability to detect clinically significant MLC errors. Radiother Oncol 2019. [DOI: 10.1016/s0167-8140(19)32214-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Giżyńska M, Witkowska J, Karpowicz P, Rostankowski R, Chocron ES, Pickering AM, Osmulski P, Gaczynska M, Jankowska E. Proline- and Arginine-Rich Peptides as Flexible Allosteric Modulators of Human Proteasome Activity. J Med Chem 2018; 62:359-370. [PMID: 30452262 PMCID: PMC6796967 DOI: 10.1021/acs.jmedchem.8b01025] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
![]()
Proline-
and arginine-rich peptide PR11 is an allosteric inhibitor
of 20S proteasome. We modified its sequence inter alia by introducing
HbYX, RYX, or RHbX C-terminal extensions (Hb, hydrophobic moiety;
R, arginine; Y, tyrosine; X, any residue). Consequently, we were able
to improve inhibitory potency or to convert inhibitors into strong
activators: the former with an aromatic penultimate Hb residue and
the latter with the HbYX motif. The PR peptide activator stimulated
20S proteasome in vitro to efficiently degrade protein substrates,
such as α-synuclein and enolase, but also activated proteasome
in cultured fibroblasts. The positive and negative PR modulators differently
influenced the proteasome conformational dynamics and affected opening
of the substrate entry pore. The resolved crystal structure showed
PR inhibitor bound far from the active sites, at the proteasome outer
face, in the pocket used by natural activators. Our studies indicate
the opportunity to tune proteasome activity by allosteric regulators
based on PR peptide scaffold.
Collapse
Affiliation(s)
- Małgorzata Giżyńska
- Department of Biomedical Chemistry, Faculty of Chemistry , University of Gdansk , Wita Stwosza 63 , 80-308 Gdansk , Poland
| | - Julia Witkowska
- Department of Biomedical Chemistry, Faculty of Chemistry , University of Gdansk , Wita Stwosza 63 , 80-308 Gdansk , Poland
| | - Przemysław Karpowicz
- Department of Biomedical Chemistry, Faculty of Chemistry , University of Gdansk , Wita Stwosza 63 , 80-308 Gdansk , Poland
| | - Rafał Rostankowski
- Department of Biomedical Chemistry, Faculty of Chemistry , University of Gdansk , Wita Stwosza 63 , 80-308 Gdansk , Poland
| | - Estrella S Chocron
- Department of Molecular Medicine, The Barshop Institute for Longevity and Aging Studies , University of Texas Health Science Center , 15355 Lambda Drive , San Antonio , Texas 78245 , United States
| | - Andrew M Pickering
- Department of Molecular Medicine, The Barshop Institute for Longevity and Aging Studies , University of Texas Health Science Center , 15355 Lambda Drive , San Antonio , Texas 78245 , United States
| | - Pawel Osmulski
- Department of Molecular Medicine, Institute of Biotechnology , University of Texas Health Science Center , 15355 Lambda Drive , San Antonio , Texas 78245 , United States
| | - Maria Gaczynska
- Department of Molecular Medicine, Institute of Biotechnology , University of Texas Health Science Center , 15355 Lambda Drive , San Antonio , Texas 78245 , United States
| | - Elżbieta Jankowska
- Department of Biomedical Chemistry, Faculty of Chemistry , University of Gdansk , Wita Stwosza 63 , 80-308 Gdansk , Poland
| |
Collapse
|
10
|
Witkowska J, Giżyńska M, Grudnik P, Golik P, Karpowicz P, Giełdoń A, Dubin G, Jankowska E. Crystal structure of a low molecular weight activator Blm-pep with yeast 20S proteasome - insights into the enzyme activation mechanism. Sci Rep 2017; 7:6177. [PMID: 28733623 PMCID: PMC5522460 DOI: 10.1038/s41598-017-05997-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2017] [Accepted: 06/28/2017] [Indexed: 11/22/2022] Open
Abstract
Proteasomes are responsible for protein turnover in eukaryotic cells, degrading short-lived species but also removing improperly folded or oxidatively damaged ones. Dysfunction of a proteasome results in gradual accumulation of misfolded/damaged proteins, leading to their aggregation. It has been postulated that proteasome activators may facilitate removal of such aggregation-prone proteins and thus prevent development of neurodegenerative disorders. However, the discovery of pharmacologically relevant compounds is hindered by insufficient structural understanding of the activation process. In this study we provide a model peptidic activator of human proteasome and analyze the structure-activity relationship within this novel scaffold. The binding mode of the activator at the relevant pocket within the proteasome has been determined by X-ray crystallography. This crystal structure provides an important basis for rational design of pharmacological compounds. Moreover, by providing a novel insight into the proteasome gating mechanism, our results allow the commonly accepted model of proteasome regulation to be revisited.
Collapse
Affiliation(s)
- Julia Witkowska
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308, Gdańsk, Poland
| | - Małgorzata Giżyńska
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308, Gdańsk, Poland
| | - Przemysław Grudnik
- Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland
- Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland
| | - Przemysław Golik
- Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland
- Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland
| | - Przemysław Karpowicz
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308, Gdańsk, Poland
| | - Artur Giełdoń
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308, Gdańsk, Poland
| | - Grzegorz Dubin
- Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
- Malopolska Centre of Biotechnology, Jagiellonian University, Gronostajowa 7, 30-387, Krakow, Poland.
| | - Elżbieta Jankowska
- Faculty of Chemistry, University of Gdańsk, Wita Stwosza 63, 80-308, Gdańsk, Poland.
| |
Collapse
|
11
|
Karpowicz P, Osmulski PA, Witkowska J, Sikorska E, Giżyńska M, Belczyk-Ciesielska A, Gaczynska ME, Jankowska E. Interplay between Structure and Charge as a Key to Allosteric Modulation of Human 20S Proteasome by the Basic Fragment of HIV-1 Tat Protein. PLoS One 2015; 10:e0143038. [PMID: 26575189 PMCID: PMC4648528 DOI: 10.1371/journal.pone.0143038] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2015] [Accepted: 10/29/2015] [Indexed: 12/25/2022] Open
Abstract
The proteasome is a giant protease responsible for degradation of the majority of cytosolic proteins. Competitive inhibitors of the proteasome are used against aggressive blood cancers. However, broadening the use of proteasome-targeting drugs requires new mechanistic approaches to the enzyme's inhibition. In our previous studies we described Tat1 peptide, an allosteric inhibitor of the proteasome derived from a fragment of the basic domain of HIV-Tat1 protein. Here, we attempted to dissect the structural determinants of the proteasome inhibition by Tat1. Single- and multiple- alanine walking scans were performed. Tat1 analogs with stabilized beta-turn conformation at positions 4-5 and 8-9, pointed out by the molecular dynamics modeling and the alanine scan, were synthesized. Structure of Tat1 analogs were analyzed by circular dichroism, Fourier transform infrared and nuclear magnetic resonance spectroscopy studies, supplemented by molecular dynamics simulations. Biological activity tests and structural studies revealed that high flexibility and exposed positive charge are hallmarks of Tat1 peptide. Interestingly, stabilization of a beta-turn at the 8-9 position was necessary to significantly improve the inhibitory potency.
Collapse
Affiliation(s)
- Przemysław Karpowicz
- Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
- Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Paweł A. Osmulski
- Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Julia Witkowska
- Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
| | - Emilia Sikorska
- Department of Organic Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
| | - Małgorzata Giżyńska
- Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
| | | | - Maria E. Gaczynska
- Department of Molecular Medicine, Institute of Biotechnology, University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States of America
| | - Elżbieta Jankowska
- Department of Biomedical Chemistry, Faculty of Chemistry, University of Gdańsk, Gdańsk, Poland
| |
Collapse
|